We are a global life sciences company active in more than 25 countries, driving innovation in drug development, manufacturing, and distribution to improve patient outcomes worldwide.
2016
Founded in Chicago
25+
Countries served
40+
Years of combined leadership experience
Aardvark signs deal to commercialize two Oncology Drugs in Saudi Arabia
With a global market cap of $8B USD, Aardvark Pharma plans to take significant market share beginning in 2028 (May 2026).
Aardvark begins R&D for 10 drugs for its USA portfolio
Aardvark Pharma initiates research to register 10 oncology drugs with the US FDA by 2032 (October 2025).
Aardvark commits to register pain medication with Mexico Cofepris by 2027
With an annual market cap of $1B USD, Aardvark Pharma plans to achieve large market share over its commercialization (February 2025).
